000 05329cam a2200457Ii 4500
999 _c96648
_d96648
_x1
001 96648
003 ES-MaUEC
005 20230102112804.0
006 m o d
007 cr cnu|||unuuu
008 171101s2017 sz a ob 000 0 eng d
020 _a3319641131
_q(electronic bk.)
020 _a9783319641133
_q(electronic bk.)
020 _z3319641123
020 _z9783319641126
040 _aN$T
_beng
_erda
_epn
_cN$T
_dN$T
_dYDX
_dGW5XE
_dUAB
_dDKU
_dEBLCP
_dAZU
_dOCLCF
_dUPM
_dIOG
_dJG0
_dCOO
_dOCLCQ
_dES-MaUEC
_bspa
050 4 _aQR245
_b2017 EB
245 0 0 _aCurrent progress in medical mycology
_cHéctor M. Mora-Montes, Leila M. Lopes-Bezerra, editors.
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2017
264 4 _c2017
300 _a1 recurso en línea
_bilustraciones
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
500 _a
504 _aIncluye referencias bibliográficas
505 0 _a""Preface""; ""Contents""; ""Contributors""; ""Chapter 1: Introduction to Medical Mycology""; ""1.1 Definition and Structure""; ""1.2 Emergence of Challenge Due to Fungal Infections""; ""1.3 Spectrum of Fungal Infections""; ""1.3.1 Superficial Mycoses""; ""1.3.2 Invasive/Opportunistic Mycoses""; ""1.3.3 Endemic Mycoses""; ""1.3.4 Allergic Manifestations""; ""1.4 Classification""; ""1.5 Epidemiology of Fungal Infections""; ""1.5.1 Global Burden of Disease""; ""1.5.2 Predisposing Factors for Fungal Infections""; ""1.5.3 Geographical Distribution""
505 8 _a""1.5.4 Community Acquired Fungal Infections""""1.5.5 Nosocomial Fungal Infections""; ""1.6 Fungal Infection Immunity and Pathogenesis""; ""1.6.1 Innate Immunity""; ""1.6.2 Adaptive Immunity""; ""1.6.3 Fungal Virulence""; ""1.6.4 Tissue Reaction""; ""1.7 Diagnosis of Fungal Infections""; ""1.7.1 Radiological Imaging""; ""1.7.2 Conventional and Culture Based Diagnosis""; ""1.7.3 Sepsis Biomarkers""; ""1.7.4 Serology""; ""1.7.5 Molecular Detection""; ""1.8 Treatment""; ""1.9 Fungal Vaccines""; ""References""; ""Chapter 2: Antifungal Drugs""
505 8 _a""2.1 Polyenes (Amphotericin B Deoxycholate and Its Lipid-­Associated Formulations)""""2.1.1 Amphotericin B Deoxicholate""; ""2.1.1.1 Chemical Structure""; ""2.1.1.2 Mechanism of Action""; ""2.1.1.3 Pharmacokinetics and Pharmacodynamics""; ""2.1.1.4 Spectrum of Activities and Resistance""; ""2.1.1.5 Clinical Uses""; ""2.1.1.6 Dosing""; ""2.1.1.7 Adverse Events and Toxicity""; ""2.1.1.8 Contraindication""; ""2.1.1.9 Drug Interactions""; ""2.1.1.10 Use in Special Population""; ""2.1.2 Lipid Formulations of Amphotericin B""; ""2.1.2.1 Dosing""; ""2.1.2.2 Adverse Events and Toxicity""
505 8 _a""2.2 Triazole Antifungal Agents""""2.2.1 General Properties""; ""2.2.1.1 Chemical Structure""; ""2.2.1.2 Mechanism of Action""; ""2.2.1.3 Pharmacokinetics""; ""2.2.1.4 Spectrum of Activity and Resistance""; ""2.2.1.5 Clinical Utility""; ""2.2.1.6 Adverse Events and Drug Interactions""; ""2.2.1.7 Dosing and Administration. Use in Special Populations""; ""2.2.2 Individual Agents""; ""2.2.2.1 Itraconazole""; ""2.2.2.2 Fluconazole""; ""2.2.2.3 Voriconazole""; ""2.2.2.4 Posaconazole""; ""2.2.2.5 Isavuconazole""
505 8 _a""2.2.3 Newer and Investigational Agents: Efinaconazole, Albaconazole, Ravuconazole and Others""""2.3 Echinocandins""; ""2.3.1 Chemical Structure""; ""2.3.2 Mechanism of Action""; ""2.3.3 Pharmacokinetics and Pharmacodynamics""; ""2.3.4 Spectrum of Activity and Resistance""; ""2.3.5 Clinical Uses""; ""2.3.6 Adverse Events and Toxicity""; ""2.3.7 Drug Interactions""; ""2.3.8 Use in Special Population and Dose Adjustments""; ""2.3.9 Adult Dosing""; ""2.3.10 New Echinocandin""; ""2.4 Flucytosine""; ""2.4.1 Chemical Structure""; ""2.4.2 Mechanism of Action""
520 3 _aInfections caused by fungi have recently attracted the attention of both clinicians and basic researchers given the heavy burden they represent for any health system. The mortality and morbidity rates associated to mycosis are progressively rising simply because some of these diseases are still neglected by health-care workers and due to the changing sensitivity to antifungal drugs displayed by these organisms. In this book, both researchers and clinicians working in the medical mycology field explore the most recent literature about specific mycosis; placing in one concise chapter thoroughly revisions of the current knowledge on virulence factors, recognition by immune cells, immunoevasion, epidemiology, new diagnosis trends and therapeutics. This book is recommended to researchers, physicians and students interested in medical mycology.
988 _aEBOOK, asignarmaterias, EBSPRINGER_2017
650 7 _aMicología médica
_2embne
_0(OCoLC)fst01014378
_0
_9405095
700 1 _aLopes-Bezerra, Leila M.,
_eeditor literario
700 1 _aMora-Montes, Hector Manuel,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-64113-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI